Top Markets
Coin of the day
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Classement en actions #14552
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Prix de l'action
$0.88126199
Capitalisation boursière
$409.74M
Changement (1 jour)
0.51%
Changement (1 an)
58.84%
Pays
SE
Échange Egetis Therapeutics AB (publ) (EGTX)

Catégorie

Ratio P/S pour Egetis Therapeutics AB (publ) (EGTX)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Egetis Therapeutics AB (publ), le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Egetis Therapeutics AB (publ) de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.95 -
US
12.19 -
NL
3.75 -
AU
24.99 -
US
- -
CH